KLRS Kalaris Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: KLRS
Price (delayed)
$2.75
Market cap
$51.43M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$8.27
Enterprise value
-$50.03M
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The
Highlights
Kalaris Therapeutics's debt has plunged by 100% from the previous quarter and by 100% YoY
KLRS's EPS has soared by 76% YoY and by 29% QoQ
The equity has surged by 166% since the previous quarter but it has declined by 47% year-on-year
The quick ratio has declined by 23% year-on-year
Key stats
What are the main financial stats of KLRS
Market
Valuations
Earnings
Shares outstanding
18.7M
Market cap
$51.43M
Enterprise value
-$50.03M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.22
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$43.5M
Net income
-$38.67M
EBIT
-$37.22M
EBITDA
-$37.16M
Free cash flow
-$30.77M
Per share
Balance sheet
Liquidity
EPS
-$8.27
EPS diluted
-$8.27
Free cash flow per share
-$7.59
Book value per share
$12.66
Revenue per share
$0
TBVPS
$25.44
Total assets
$103.09M
Total liabilities
$39.22M
Debt
$0
Equity
$63.87M
Working capital
$95.04M
Debt to equity
0
Current ratio
14.31
Quick ratio
14.21
Net debt/EBITDA
2.73
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-42.6%
Return on equity
-74.1%
Return on invested capital
-489.1%
Return on capital employed
-38.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KLRS stock price
How has the Kalaris Therapeutics stock price performed over time
Intraday
2.23%
1 week
-0.72%
1 month
3%
1 year
-84.15%
YTD
-71.53%
QTD
3%
Financial performance
How have Kalaris Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$43.5M
Net income
-$38.67M
Gross margin
N/A
Net margin
N/A
The net income has soared by 75% year-on-year and by 34% since the previous quarter
The operating income has soared by 73% YoY and by 34% from the previous quarter
Price vs fundamentals
How does KLRS's price correlate with its fundamentals
Growth
What is Kalaris Therapeutics's growth rate over time
Valuation
What is Kalaris Therapeutics stock price valuation
P/E
N/A
P/B
0.22
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
KLRS's EPS has soared by 76% YoY and by 29% QoQ
The equity has surged by 166% since the previous quarter but it has declined by 47% year-on-year
The price to book (P/B) is 92% less than the 5-year quarterly average of 2.6
Efficiency
How efficient is Kalaris Therapeutics business performance
Kalaris Therapeutics's return on invested capital has shrunk by 117% QoQ
The return on assets rose by 40% year-on-year and by 27% since the previous quarter
KLRS's return on equity is up by 16% since the previous quarter and by 16% year-on-year
Dividends
What is KLRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KLRS.
Financial health
How did Kalaris Therapeutics financials performed over time
The total assets is 163% greater than the total liabilities
KLRS's total liabilities has surged by 65% year-on-year but it is down by 31% since the previous quarter
The total assets has declined by 28% year-on-year
Kalaris Therapeutics's debt is 100% less than its equity
The equity has surged by 166% since the previous quarter but it has declined by 47% year-on-year
KLRS's debt to equity has soared by 100% since the previous quarter but it has dropped by 100% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.